Identification of mutated and non-mutated tumor-associated antigens in glioblastoma

Identification of mutated and non-mutated tumor-associated antigens in glioblastoma - GAPVAC (Glioma actively personalized vaccine consortium) part 1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38803

Enrollment

Registered

2013-04-24

Start date

2013-04-25

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma glioblastoma multiforme

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age: >= 18 years • Unresected primary or recurrent brain tumor • Haemoglobin >= 10 g/100 ml • Able to understand the research and give written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Mutated and non-mutated tumor-associated antigens in glioblastoma	—

Secondary

Measure	Time frame
EU harmonized procedures for imuunmonitoring. A glioblastoma specific sHLA:peptidome.	—

Countries

Netherlands

Outcome results